Unicycive Therapeutics (UNCY) Assets Average (2021 - 2026)

Unicycive Therapeutics (UNCY) has 6 years of Assets Average data on file, last reported at $56.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 90.46% year-over-year to $56.8 million; the trailing twelve-month figure through Mar 2026 stood at $56.8 million (up 90.46% YoY), and the FY2025 full-year result was $40.4 million, up 76.2% from the prior year.
• Assets Average for Q1 2026 stood at $56.8 million, up from $49.9 million in the prior quarter.
• Across five years, Assets Average topped out at $56.8 million in Q1 2026 and bottomed at $6.5 million in Q4 2022.
• The 5-year median for Assets Average is $29.0 million (2025), against an average of $28.9 million.
• The widest annual swing landed in 2022, when Assets Average plunged 66.27%; it then jumped 158.81% in 2023.
• A 5-year view of Assets Average shows it stood at $6.5 million in 2022, then surged by 158.81% to $16.8 million in 2023, then soared by 108.85% to $35.1 million in 2024, then soared by 42.0% to $49.9 million in 2025, then grew by 13.83% to $56.8 million in 2026.
• The last three Assets Average figures came in at $56.8 million (Q1 2026), $49.9 million (Q4 2025), and $40.3 million (Q3 2025), per Business Quant data.

Peer Comparison